MUMBAI, India, Oct. 24 -- Intellectual Property India has published a patent application (202441031399 A) filed by MSN Laboratories Private Limited, R&D Center, Hyderabad, Telangana, on April 19, 2024, for 'pharmaceutical comprising rimegepant.'
Inventor(s) include Ravi Kumar Nithiyanandam; Dr. Mahesh N. Padamwar; and Dr. Sabyasachi Swain.
The application for the patent was published on Oct. 24, under issue no. 43/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to pharmaceutical comprising rimegepant or a pharmaceutically acceptable salts thereof and process for preparation which is simple, economic, cost-effective, and industrially amenable to scale up. Further, the said invention is used for the acute treatment of migraine with or without aura in adults and preventive treatment of episodic migraine in adults."
Disclaimer: Curated by HT Syndication.
